Abstract
Platelet [3H] paroxetine binding was measured in 73 depressed patients and in 64 healthy volunteers. No differences were found in Bmax or Kd either overall, or when the 61 depressed subjects who had never received psychotropic drugs were analysed separately. Within the depressed group, no differences in Bmax or Kd were found between subgroups divided on the basis of endogenicity, suicidal thoughts or severity of depression. None of the subgroups differed significantly from controls. Forty of the depressed subjects were retested after 6 weeks' treatment with fluoxetine (n=22) or lofepramine (n=18). Treatment was not associated with any change in Bmax but a similar and significant increase in Kd was noted following treatment with either antidepressant. Neither pre- nor post-treatment platelet binding parameters appeared to relate to clinical response to treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (3rd edition, revised). American Psychiatric Association, Washington
Andersson A, Eriksson A, Marcusson J (1992) Unaltered number of brain serotonin uptake sites in suicide victims. J Psychopharmacol 6:509–513
Carney MWP, Roth M, Garside RF (1965) The diagnosis of depressive syndromes and the prediction of ECT response. Br J Psychiatry 140:659–674
Cheetham SC, Viggers JA, Slater NA, Heal DJ, Buckett WR (1993) [3H] Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various anti-depressant treatments. Neuropharmacology 32:737–743
D'Haenan H, De Waele M, Leysen JE (1988) Platelet3H-paroxetine binding in depressed patients. Psychiatry Res 26:11–17
Elliott JM (1991) Peripheral markers in affective disorders. In: Horton RW, Katona C (eds) Biological aspects of affective disorders. Academic Press, London, pp 95–144
Graham D, Tahraoui L, Langer SZ (1987) Effects of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H] paroxetine binding to rat cortical membranes. Neuropharmacology 26:1087–1092
Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296
Healy D, Theodorou AE, Whitehouse AW, Lawrence KM, White W, Wilton-Cox H, Kerry SM, Horton RW, Paykel ES (1990)3H-Imipramine binding to previously frozen platelet membranes from depressed patients before and after treatment. Br J Psychiatry 157:208–215
Hrdina P (1984) Differentiation of two components of specific [3H] imipramine binding in rat brain. Eur J Pharmacol 102:481–488
Hrdina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M (1993) 5-HT uptake sites and 5-HT2receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res 614:37–44
Lawrence KM, De Paermentier F, Cheetham SC, Crompton MR, Katona CLE, Horton RW (1990) Brain 5-HT uptake sites, labelled with3H paroxetine, in antidepressant-free depressed suicides. Brain Res 526:17–22
Lawrence KM, Falkowski J, Jacobson RR, Horton RW (1993) Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine. Psychopharmacology 110:235–239
Marcusson JO, Ross SB (1990) Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets. Psychopharmacology 102:145–155
Mellerup ET, Langer SZ (1991) Validity of imipramine platelet binding sites as a biological marker of endogenous depression. Pharmacopsychiatry 23:113–117
Mellerup ET, Plenge P, Engelstoft M (1983) High affinity binding of [3H] paroxetine and [3H] imipramine to human platelet membranes. Eur J Pharmacol 96:303–309
Montgomery S, Asberg M (1979) A new depression rating scale designed to be sensitive to change. Br J Psychiatry 134: 382–389
Stahl SM (1977) The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 34:509–516
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lawrence, K.M., Katona, C.L.E., Abou-Saleh, M.T. et al. Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine. Psychopharmacology 115, 261–264 (1994). https://doi.org/10.1007/BF02244781
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244781